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In 1983, during the earliest days of AIDS research, Debo-
rah Anderson and her colleagues in Boston, Massachusetts
hypothesized that AIDS was transmitted by virally-
infected "Trojan horse leukocytes" in semen [1]. This pre-
diction has been supported by numerous studies over the
past two decades, although many questions remain con-
cerning HIV infection of the male genital tract. In this
issue of AIDS Research and Therapy, the Anderson group
presents an important research tool to help address some
of the critical unanswered questions in this area [2].
A series of salient studies have shaped current concepts on
HIV-1 in semen. In 1984, Ho et al. described retroviral
particles and infected cells in the semen of a homosexual
man with AIDS [3]. Shortly thereafter Stewart et al.
reported infection of four out of eight women following
artificial insemination with semen from one seroconvert-
ing individual [4], leading to a mandatory semen quaran-
tine requirement and HIV testing of semen donors in
Assisted Reproduction clinics. At that time, the detection
of HIV, which was still termed HTLV-III, was not routinely
feasible from blood, let alone from semen. Since then,
technological advances have enabled the detection and
quantitation of HIV-1 RNA and proviral DNA and greatly
improved our understanding of the dynamics of HIV-1 in
semen and sexual transmission risks. HIV-infected white
blood cells have been detected throughout the male geni-
tal tract, and in preejaculatory fluid and semen from
HIV+men [5,8]; the weight of evidence suggests that
sperm are not infectious [9], leading to the successful
development of sperm wash procedures to reduce the risk
of HIV transmission from HIV-infected men to uninfected
partners through assisted reproduction techniques [10]. A
combination of epidemiological and clinical research
studies have determined a relationship between HIV-1
RNA viral load in semen and the risk of sexual transmis-
sion. The most important factors associated with
increased HIV viral loads in semen and risk of sexual
transmission are: HIV-viremia and coinfections with other
sexually transmitted pathogens [11,12]. HAART dramati-
cally suppresses HIV-1 RNA viral loads in blood and
semen, but HIV-1 proviral DNA can persist in semen
WBCs for months after the initiation of HAART [13]. Data
from other studies showing discordantly higher levels of
HIV in semen than blood in some individuals support this
finding. In addition, molecular sequencing studies indi-
cate that the male genital tract is a compartment, like the
central nervous system, in which HIV-1 replication and
divergent evolution can occur under the influence of local
factors [14]. Several clinically important questions
remain: 1) Is HIV-1 primarily sexually transmitted by
infected cells, cell-free virus or both? 2) What is the origin
of cell-free and cell-associated HIV-1 in semen? 3) Are
men on HAART with undetectable peripheral viral loads
capable of sexually transmitting drug-resistant HIV-1?
Episomal HIV-1 c-DNA, a by-product of HIV-1 infection,
is currently used in clinical trials as a marker of residual
viral replication and potential evolution of drug resistance
mutations in viral reservoir sites in individuals on HAART
[15]. Such a marker would be useful for identifying sites
of HIV-1 replication in the male genital tract, and for
monitoring cryptic HIV-1 infection in the genital tract of
men on antiretroviral therapy. The only reported study
that measured episomal HIV-1 c-DNA in blood and
semen of men before and after initiation of HAART failed
to detect HIV episomal 2-LTR cDNA in semen [16]. The
method used to recover HIV-infected cells from semen in
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this study – separation of seminal WBC on Ficoll gradients
– likely decreased the sensitivity of HIV episomal c-DNA
detection because infected macrophages and a proportion
of infected T-cells are lost through this approach. The
paper by Xu et al. used a direct lysis technique optimizing
recovery of DNA from HIV-infected cells in semen. Using
this approach, combined with quantitative PCR and DNA
sequencing, the investigators show that episomal 2-LTR
cDNA is detectable in semen from a subset of men with
other evidence of seminal HIV-1 infection. The marker
was not detected in semen from 22 men at 1- and 6-
months after peripheral viral suppression due to addition
of indinavir to their ART regimen. This study is important
because it provides a new tool for studying HIV infection
of the male genital tract, and provides preliminary evi-
dence that cryptic HIV-1 infection may not occur in the
genital tract of men on HAART. Further studies will surely
follow to confirm and extend these observations.
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